DAC treatment upregulated NY-ESO-1 and MHC class I expression in ovarian cancer cell lines in vitro with the expectation of increased recognition by antigen-reactive CD8+ T-cells [203]. This evidence concerns the gene CD8A and ovarian carcinoma.